

**REGISTERED COMPANY NUMBER: 07955451 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1147457**

**Report of the Trustees and**  
**Financial Statements for the Year Ended 31 December 2020**  
**for**  
**THE HPV AND ANAL CANCER FOUNDATION**  
**LIMITED**

Knox Cropper LLP  
Chartered Accountants  
65 Leadenhall Street  
London  
EC3A 2AD

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Contents of the Financial Statements  
for the Year Ended 31 December 2020**

---

	<b>Page</b>
<b>Reference and Administrative Details</b>	1
<b>Report of the Trustees</b>	2 to 14
<b>Independent Examiner's Report</b>	15
<b>Statement of Financial Activities</b>	16
<b>Balance Sheet</b>	17
<b>Notes to the Financial Statements</b>	18 to 26
<b>Detailed Statement of Financial Activities</b>	27 to 28

---

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Reference and Administrative Details  
for the Year Ended 31 December 2020**

---

<b>TRUSTEES</b>	C Almada J Almada T Almada C Levett
<b>REGISTERED OFFICE</b>	Kemp House 160 City Road London London EC1V 2NX
<b>REGISTERED COMPANY NUMBER</b>	07955451 (England and Wales)
<b>REGISTERED CHARITY NUMBER</b>	1147457
<b>INDEPENDENT EXAMINER</b>	Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD
<b>SOLICITORS</b>	Stone King 16 St. John's Lane London EC1M 4BS
<b>BANKERS</b>	HSBC 455 Strand London WC2R 0RH

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Report of the Trustees  
for the Year Ended 31 December 2020**

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 27. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.



# THE HPV AND ANAL CANCER FOUNDATION LIMITED

## Report of the Trustees for the Year Ended 31 December 2020

---

### OBJECTIVES AND ACTIVITIES

#### Objectives and aims

##### History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

##### Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

##### Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

##### The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus now turns to securing the same protection for boys as well as girls across Europe.

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Report of the Trustees  
for the Year Ended 31 December 2020**

---

**Strategies to Achieve Our Goals**

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES KEY ACHIEVEMENTS IN 2020**

##### **Foundation Restructure**

In 2020 we continue our two-pronged programmatic approach, operating under the umbrella of The Anal Cancer Foundation (registered as The HPV and Anal Cancer Foundation Limited in the UK).

The Anal Cancer Foundation: Improve the lives of anal cancer patients through prevention, treatment, and support.

The NOMAN Campaign: End 5% of the world's cancer through global coverage of HPV immunisation for all children.

##### **NOMAN is an Island**

The NOMAN is an Island Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMEN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona - Ibiza: Row to End HPV, 141 individuals - and their hundreds of supporters - have embraced the cause and our values. These NOMEN have raised awareness about HPV-related cancers on a local, national, and international scale as well as funds to support our programmes.

In 2020, NOMAN riders took on the Haute Route Ventoux event. The Haute Route is the world's most prestigious cycling event for amateur cyclists providing unparalleled experiences with the key ingredients of 3 or 7 day professional road racing events in the most iconic cycling destinations worldwide. In October, a team of NOMAN riders took on the Haute Route Ventoux, a 3-day event comprising nearly 300km of riding and 8000 metres of height gain, raising funds to prevent 5% of cancer in the process. We are grateful for their extraordinary efforts to raise awareness around HPV-related cancers.

Additionally a group of supporters in Geneva undertook the inaugural 'Anieres Man for NOMAN' event - tackling 1.5km of swimming, 49km of cycling including 500m elevation gain, and a 13km run - all in the name of NOMAN's mission to prevent 5% of cancers.

We now look forward to the 2021 edition of our Barcelona - Ibiza: Row to End HPV races, and the Haute Route events of that summer.

##### **HPV Action**

HPV Action (HPVA) is a collaborative partnership of patient and professional organisations that are working to reduce the health burden of HPV. The HPV and Anal Cancer Foundation was a founding member of HPVA in 2013 and has since provided financial support and leadership for the coalition.

Following a five-year campaign, the Foundation and its partners in HPV Action achieved a monumental milestone to end all HPV-related cancers with the adoption of school-based vaccinations for boys.

**Report of the Trustees  
for the Year Ended 31 December 2020**

---

**OBJECTIVES AND ACTIVITIES**

HPV causes 5% of cancers worldwide in men and women. At the end of 2019, around 40 countries vaccinate boys as well as girls.

HPVA advocates equal access to HPV protection for both boys and girls to prevent a range of HPV-related conditions including cancers, precancers, and genital warts. HPVA's efforts illustrated that boys should be included in the UK HPV immunisation program to protect: (1) men and women from HPV-related anal, cervical, penile, oropharyngeal, vaginal and vulval cancers and precancers; (2) men and women from genital warts; and (3) children and adults from recurrent, respiratory papillomatosis (RRP), a rare but disabling HPV-related condition. HPVA estimates that over 2,000 men a year in the UK develop a cancer (penile, anal or oropharyngeal) caused by HPV and 5,000 women a year develop a cancer (anal, cervical, oropharyngeal, vaginal or vulval) caused by HPV. HPV additionally causes 48,000 new cases in men and 39,000 cases in women of genital warts annually. Approximately 600 adults and children in the UK have RRP.

A national HPV vaccination programme that includes all children in the UK will improve public health and health inequalities, prove cost-effective and, above all, reduce the suffering caused by cancers and diseases that are easily preventable. As part of the HPVA group, we educate MPs, ministers, governments and NHS officials on the importance of protecting all children against the carcinogenic HPV virus; inform the public; build scientific support; and engage patient, professional and other organisations in support of ending HPV and the cancers it causes.

Prior to 2019, HPV immunisation programmes in the UK were exclusively for females, with girls aged 12 and 13 routinely vaccinated predominantly via a school-based programme since 2007. Consequently, men were not protected against HPV. HPV infects both men and women, and causes cancer in both sexes, including cancers of the anus, cervix, head and neck, penis, vagina, and vulva. Many of these cancer cases are preventable if the person is immunised before they are exposed to the virus.

**HPV Action Impact 2020**

Gender-neutral HPV vaccination began in September 2019, however no announcement was made as to whether a catch-up programme would be instigated for boys aged 13-18.

In its meeting in early February 2020, the JCVI decided not to recommend a catch-up vaccination programme for older boys. HPV Action did as much as we could to advocate for a catch-up programme despite our limited capacity including meeting with JCVI/PHE in January 2020, correspondence with JCVI, the engagement of several MPs who wrote letters to ministers and tabled PQs, and a social media campaign through twitter and Facebook. Whilst this was a disappointing outcome it was felt that it was not worth continuing with this effort because it was extremely unlikely that JCVI would change its mind, especially in the context of the global vaccine shortage (predicted to last until 2023).

In March 2020 the future of HPV Action was discussed which took account of the achievement of the universal programme, the recent JCVI decision on a catch-up programme for boys, and the new ECCO HPV initiative. It was agreed that HPVA would be wound up in September, with the Jabs for the Boys website to continue as a legacy project. Numerous HPV Action members agreed to stay on a database so that they can if necessary be contacted if an issue with vaccination arises in the future, such as a fall in uptake due to anti-vaccination campaigning. A broad-based campaign in this vein played a key role in reversing a fall in vaccination uptake in Ireland in recent years.

Several members are involved in the European HPV Action Network which aims to eliminate HPV cancers in the 53 member states of the WHO European region.

**Coalition Building**

The 51 organisations in the membership of HPV Action, included:

## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES**

British Association for Sexual Health and HIV, British Association of Dental Nurses, British Association of Dental Therapists, British Dental Association, British Society for Immunology, British Society of Dental Hygiene and Therapy, Brook, Cancer Focus Northern Ireland, Children's HIV Association of the UK & Ireland (CHIVA), ENT UK, European Men's Health Forum, Faculty of General Dental Practice (UK), Faculty of Public Health, Faculty of Sexual and Reproductive Healthcare, Family Planning Association, GMFA (Gay Men's Health Charity), Herpes Viruses Association, HPV and Anal Cancer Foundation, Let's Talk About Mouth Cancer, London Cancer Alliance, London Friend, Men's Health Forum (GB), Men's Health Forum Ireland, Mouth Cancer Foundation, National Aids Manual, National Association of Laryngectomee Clubs (NALC), National Education Union, National Oral Health Promotion Group, National Union of Students, Northern Head and Neck Cancer Fund, Oral Cancer Foundation (USA), Oral Health Foundation, Primary Care Urology Society, Rainbow Project, Reproductive Health Matters, Royal College of Obstetricians and Gynaecologists, Royal Society for Public Health, The School and Public Health Nurses Association, Sexpression:UK, Society of British Dental Nurses, Society of Sexual Health Advisers, Stonewall, The Swallows Head and Neck Cancer Support Group, Tenovus, Terrence Higgins Trust, Throat Cancer Foundation, The Urology Foundation, and Wellbeing of Women.

#### **HPV Action Europe Network**

In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

NOMAN has partnered with the European Cancer Organisation to achieve this mission. The European Cancer Organisation works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through multidisciplinary and multi-professionalism. As the not-for-profit federation of member organisations working in cancer at a European level, they convene oncology professionals and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community. Together with the European Cancer Organisation, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers.

The main achievements of the HPV Action Network in 2020 were as follows:

#### **Launch of new HPV report: Viral Protection: Achieving the Possible**

In October we launched a major new report 'Viral Protection: Achieving the Possible. A Four Step Plan for Eliminating HPV Cancers in Europe' calling for a series of goals in order to prevent 67,500 cancer cases per year across the 27 EU member states, rising to 90,000 across the wider World Health Organisation (WHO) European region.

The central recommendation of our plan to eliminate HPV Cancers in Europe is as follows:

'The European Union and the wider WHO European region should commit to the core goal of matching and exceeding the WHO Global Strategy for Cervical Cancer Elimination and implement policies and strategies for the elimination of all the cancers and diseases caused by HPV.'

Action areas to achieve this goal are:

1. Universal (or 'gender-neutral') HPV vaccination for adolescents and optimal levels of uptake.
2. National organised population-based cervical cancer screening programmes using HPV testing systems and with higher levels of uptake.
3. Cancer treatments consistently and equitably offered in line with best practice guidelines and care and support that maximises patients' quality of life.

## **OBJECTIVES AND ACTIVITIES**

4. Action to improve public and professional awareness and education about HPV in order to improve vaccination and screening uptake.

We believe that the WHO's strategy for the global elimination of cervical cancer as a public health problem, is not ambitious enough. The forthcoming Europe Beating Cancer Plan, EU Cancer Mission and EU4Health Programme must include actions to eliminate all HPV Cancers. The world has used vaccines to eliminate the suffering caused by many diseases such as smallpox and polio - it is time we add HPV and the suffering it causes to this list.

The HPV Action Network urges Europe to make HPV cancer elimination a formal European shared goal. Europe's Beating Cancer Plan and other Regional/EU/National initiatives present significant opportunities for progress to be made.

### **Viral Protection highlights that:**

- A quarter (14 out of 54, 26%) of European region countries still do not vaccinate girls against HPV.
- Under a half (26 countries, 48%) vaccinate, or are planning to start vaccinating, boys as well as girls.
- Few countries meet the widely-accepted target of 80% HPV vaccination coverage.
- 16 countries have 'opportunistic' cervical cancer screening which means their success depends on the initiative of individual women and their doctors, resulting in lower uptake.
- Treatment outcomes for cancers caused by HPV vary widely across the region; for women diagnosed with cervical cancer, five-year survival rates range from 80% in Iceland to 55% in Poland and Bulgaria.
- 'Fake news' about HPV vaccination safety, widely shared via social media, has resulted in falls in uptake; in Denmark, it fell from 90% to 54%.

You can read the plan below, and find out more about the campaign here. The report was distributed to key DG Sante officials, MEPs and other health stakeholders.

### **European Cancer Summit**

NOMAN co-founder Tristan Almada was invited to address the European Cancer Summit on the role of civil society organisations in the fight to eliminate HPV Cancers in Europe, reflecting on the success of our campaign in the USA and UK to extend HPV vaccination programmes to include boys as well as girls.

Speaking alongside Professor Margaret Stanley, Emili Karafakis and Cobi Reisman, topics included public health needs, the possibility of an HPV Cancer free Europe by 2030, and tackling vaccine hesitancy.

The following resolutions were passed at the summit by attendees, following the session:

#### **Resolution 1 - Screening**

"Immediate and urgent action should be taken to ensure that cervical cancer screening programmes are not interrupted by COVID-19, especially in countries with the lowest screening rates. The adoption of HPV self-sampling must be accelerated in order to improve uptake."

#### **Resolution 2 - Vaccination**

"HPV-associated cancers are preventable by universal vaccination. Anti-vaccination misinformation is putting programmes at serious risk and all European health authorities must act now to improve public confidence in HPV vaccination."

## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES**

Other milestones included

- Presentation on HPV to ENVI Health Working Group (18 February 2020)
- Presentation to IPVS Conference (24 July 2020)
- Meeting on HPV and Europe's Beating Cancer Plan with Matthias Schuppe, DG Sante (29 July 2020)
- Presentation to the BECA Committee, EU Parliament (2 December)
- Increased stakeholder engagement in Network

The Network now has 21 members/stakeholders, shown here:  
<https://www.europeancancer.org/topic-networks/1:hpv-action.html>.

We now await the publication of the Beating Cancer Plan to see if actions on HPV have been included.

#### **Anal Cancer Foundation**

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

#### **Peer to Peer Support Programme and Thriver Education**

In the UK, about 1,500 people, and in the US, about 8,600 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries with it prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer support program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2020, the HPVACF's Peer-to-Peer programme included 558 participants.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 4000 people by the end of 2020. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 8000 times by the end of the year.

#### **International Anal Neoplasia Society (IANS)**

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES**

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develop position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represent the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.

" Encourage the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

- Develop educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.

- Develop educational materials for patients with anal neoplasia.

In 2020, IANS:

- Developed IANS COVID-19 guidelines, published in Colorectal Diseases
- Held the first IANS Virtual Standard HRA Course in November with 133 participants
- Held 11 WebRounds - nine in English, one in Portuguese, and one in Spanish
- Created European and Spanish/Portuguese Task Forces to strengthen and diversify its membership base
- Constituted Screening Task Forces that are currently working to develop international guidelines

#### **Information and Connection**

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our Living with Anal Cancer section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer support programme.

Our goal in 2020 continues to be ensuring more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources.

With the pandemic reducing the in person resources available to the anal cancer community, the need for communication with our community was more important than ever. Our communications strategy focused on consistency and 'being useful', with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

The results spoke for themselves.



## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES**

- A 17% increase in visitor sessions online
- A 15% increase in the number of pages per session
- An 8% decrease in single page sessions
- A 2.5% increase in sessions per user

Going forward, we aim to continue providing all the support the anal cancer community needs.

#### **Investing in cures: financing ground-breaking research**

As a non-profit funder of medical research motivated by personal loss, our mission is to offer new treatments to patients as quickly as possible. Our research philosophy is to invest in high-risk, high-reward projects that we believe hold tremendous promise for advancing the treatment field for anal cancer patients and other patients living with HPV-related cancers.

We accomplish this by aligning incentives across all of the relevant stakeholders, fostering collaboration wherever possible, receiving input from a board of key opinion leaders and expert advisors, and using funding to address resource gaps in preclinical and clinical settings. We collaborate with other foundations and government agencies to ensure funding for the research that we seek to advance. These partnerships have allowed us to leverage our funds to produce faster and more robust research outcomes to urgently find a cure.

The Foundation's mission is focused on improving the lives of two cancer populations specifically: people facing HPV-related cancers and people facing anal cancer (one type of HPV-related cancer). Six years ago, people who were diagnosed with these cancers in a late stage had few therapeutic options available to them. For anal cancer, no significant update to advanced cancer treatment had occurred in four decades. For HPV-related cancers, there were no clinically recognized trials seeking one therapy to treat the different-but-connected cancers simultaneously. With a few focused grants, the Foundation sought to raise the profile of these cancers, increase interest among the scientific community, spur innovative research, and deliver new drugs into the hands of patients.

The Foundation chose to invest in an emerging approach to the fight against cancer: immunotherapy. Cancer, in essence, is a failure of the immune system to "see" and dismantle abnormal cells. This breakdown allows one or multiple errant cells to multiply until they affect the functioning of the body. Immunotherapies seek to address this malfunction by modulating specific aspects of the immune system to target cancer cells.

#### **Supporting Research to Find A Cure for Multiple HPV-Related Cancers**

HPV-related cancers represent 5% of the world's cancers and treatment to cure these malignancies has barely advanced in decades. To address this vast and unmet need, the Foundation partnered with Stand Up To Cancer and the Farrah Fawcett Foundation in a \$1.2 million grant to support researchers at Dana-Farber Cancer Institute in Boston, Massachusetts, who are investigating the treatment of HPV-related cancer by harnessing the immune system against it. The study was a first of its kind as we sought a therapy to help multiple HPV-related cancers, instead of addressing each cancer individually.

The study focuses on the preclinical and clinical development of an immunotherapy treatment for patients with recurrent HPV-related anal, cervical, and head and neck cancers who have relapsed after their initial therapy as such patients have few therapeutic options available to them. A successful vaccine would be used to augment chemotherapeutic outcomes and improve survival. Specifically, this Phase 1b/2 trial tests tumor response and safety/efficacy of vaccination with E711-19 nanomer for the treatment of incurable HPV-16 related head & neck, cervical, and anal cancer in HLA-A2 positive patients. It investigates the theory of therapeutic CD8 vaccines against HPV epitopes. This project is led by Ellis L. Reinherz, M.D., Chief of the Laboratory of Immunobiology and Co-Director of the Cancer Vaccine Center at Dana-Farber and Robert I. Haddad, M.D., Disease Center Leader for Head and Neck Oncology at Dana-Farber.

## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES**

The trial was completed in 2019 and resulted in three publications. Whilst the trial agent produced no durable response in study participants, researchers studying the results were able to gain a better understanding of the diversity of cancer cells in HPV cancers as well as why certain HPV therapeutic vaccines might fail. Additionally, the trial improved care in the HPV cancer space by creating connections among HPV laboratory and clinical investigators across the Boston research community, and more broadly, across the national HPV advocacy community. As the first trial to investigate a therapeutic vaccine for multiple HPV cancers, it was a critical first step towards unifying a once-siloed research community to find a cure for all HPV cancers. As a result, where once each HPV cancer was researched solely in individual trials, there are now multiple clinical trials specifically researching agents to treat and cure all HPV cancers.

Encouraging the scientific field to view these cancers comprehensively resulted in a new approach for generating promising treatments on behalf of the hundreds of thousands of people living with HPV-related cancers. In light of this significant shift led by the Foundation, there are now several phase I and II trials underway that seek to find a treatment for multiple HPV-related cancers at the same time.

#### **LOOKING AHEAD: 2021**

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eradicate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

Although the UK began vaccinating boys against HPV as pupils return to schools in September 2019, we will continue to work with Public Health England and other stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12-13 year old boys is as high as possible. The interruption caused by the pandemic will undoubtedly affect vaccination rates in the UK and beyond. In the wake of a growing vaccine hesitancy sentiment, our work is more important than ever.

Our advocacy focus now turns towards building our nascent partnership with the European Cancer Organisation and the HPV Action Network in order to achieve change across the European continent. The EU Beating Cancer Plan set to be announced in 2021 will address cancer-related inequalities between and within Member States with actions to support, coordinate, and complement Member States' efforts. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer.

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which to broadcast our message. In 2021, we will continue to partner with the Haute Route on further cycling events as their European Charity Partner, furthering the reach of our message to prevent 5% of cancer, and providing the opportunity to reconnect with the cyclists within our community. Additionally, the return of our flagship Barcelona - Ibiza: Row to End HPV races will as ever, capture the imagination of, and spread the message of how we can prevent HPV cancers, to a broader audience.

We remain committed to finding better cures for patients and creating the essential research building blocks that currently do not exist. For four decades, treatment for all stages of anal cancer had remained essentially the same with no FDA-approved drugs targeted and the same toxic side effects as in the 1970's. Our breakthrough with MD Anderson Cancer Center is offering new hope to anal cancer patients and we look forward to further progress in the search for a cure.

## **THE HPV AND ANAL CANCER FOUNDATION LIMITED**

### **Report of the Trustees for the Year Ended 31 December 2020**

---

#### **OBJECTIVES AND ACTIVITIES**

We will continue to provide anal cancer thrivers with information and support they need on their journey. In addition, our Peer to Peer support programme retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

#### **Public benefit**

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

#### **FINANCIAL REVIEW**

##### **Financial position**

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2020 was £90,186 and expenditure was £129,268.

##### **Reserves policy**

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

##### **Going concern**

As stated in note 20, the Trustees have considered the effect of the COVID-19 pandemic. The Trustees consider that the pandemic is likely to cause disruption to the Charity's activities but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future.

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

##### **Governing document, structure and management**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Report of the Trustees  
for the Year Ended 31 December 2020**

---

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charity on the 25 May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 21. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws and policies.

**Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and systems are in place to mitigate those risks which the charity may face.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on .....27.09.2021..... and signed on its behalf by:



.....

T Almada - Trustee

**Independent Examiner's Report to the Trustees of  
The HPV and Anal Cancer Foundation  
Limited**

---

**Independent examiner's report to the trustees of The HPV and Anal Cancer Foundation Limited ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2020.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst  
FCA  
Knox Cropper LLP  
Chartered Accountants  
65 Leadenhall Street  
London  
EC3A 2AD

28/09/2021

Date: .....

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Statement of Financial Activities  
(Incorporating an Income and Expenditure Account)  
for the Year Ended 31 December 2020**

	Notes	Unrestricted funds £	Restricted funds £	<b>2020 Total funds £</b>	2019 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		<b>17,061</b>	-	<b>17,061</b>	11,790
Other trading activities	2	<b>73,105</b>	-	<b>73,105</b>	428,398
Investment income	3	<b>20</b>	-	<b>20</b>	55
<b>Total</b>		<b>90,186</b>	-	<b>90,186</b>	440,243
<b>EXPENDITURE ON</b>					
Raising funds	4	<b>20,478</b>	-	<b>20,478</b>	147,779
<b>Charitable activities</b>	5				
Care and Support		<b>27,417</b>	-	<b>27,417</b>	8,664
Awareness Raising		<b>76,467</b>	-	<b>76,467</b>	187,219
Research for a Cure		<b>4,906</b>	-	<b>4,906</b>	3,828
<b>Total</b>		<b>129,268</b>	-	<b>129,268</b>	347,490
<b>NET INCOME/(EXPENDITURE)</b>		<b>(39,082)</b>	-	<b>(39,082)</b>	92,753
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		<b>153,171</b>	<b>13,100</b>	<b>166,271</b>	73,518
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>114,089</b>	<b>13,100</b>	<b>127,189</b>	166,271

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED (REGISTERED NUMBER: 07955451)**

**Balance Sheet  
31 December 2020**

	Notes	2020 £	2019 £
<b>CURRENT ASSETS</b>			
Debtors	14	218	11,999
Cash at bank		<b>135,806</b>	160,983
		<b>136,024</b>	172,982
<b>CREDITORS</b>			
Amounts falling due within one year	15	<b>(8,835)</b>	(6,711)
<b>NET CURRENT ASSETS</b>		<b>127,189</b>	166,271
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>127,189</b>	166,271
<b>NET ASSETS</b>		<b>127,189</b>	166,271
<b>FUNDS</b>	18		
Unrestricted funds		<b>114,089</b>	153,171
Restricted funds		<b>13,100</b>	13,100
<b>TOTAL FUNDS</b>		<b>127,189</b>	166,271

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on .....**27.09.2021**..... and were signed on its behalf by:



.....  
T Almada - Trustee

The notes form part of these financial statements

## **1. ACCOUNTING POLICIES**

### **Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

### **Going Concern**

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

### **Financial reporting standard 102 - reduced disclosure exemptions**

The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

### **Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

### **Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories - over 3 years

### **Taxation**

The charity is exempt from corporation tax on its charitable activities.

### **Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.



**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**1. ACCOUNTING POLICIES - continued**

**Fund accounting**

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Pension costs and other post-retirement benefits**

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

**Judgments and key sources of estimation uncertainty**

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have a significant effect on amounts recognised in the financial statements.

**2. OTHER TRADING ACTIVITIES**

	<b>2020</b>	2019
	<b>£</b>	£
Fundraising events	<b>73,105</b>	428,398

**3. INVESTMENT INCOME**

	<b>2020</b>	2019
	<b>£</b>	£
Deposit account interest	<b>20</b>	55

**4. RAISING FUNDS**

**Raising donations and legacies**

	<b>2020</b>	2019
	<b>£</b>	£
Staff costs	<b>5,611</b>	-
Development expenses	<b>152</b>	638
Marketing	-	9,318
Miscellaneous expenses	-	49
Donor software subscription	<b>1,174</b>	1,896
Event Expenses	<b>4,226</b>	117,494
Media	<b>3,300</b>	4,149
Support costs (Operating)	<b>6,015</b>	14,235
	<b>20,478</b>	147,779

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**5. CHARITABLE ACTIVITIES COSTS**

	Direct Costs (see note 6) £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Care and Support	23,114	-	4,303	27,417
Awareness Raising	36,094	13,235	27,138	76,467
Research for a Cure	863	-	4,043	4,906
	<u>60,071</u>	<u>13,235</u>	<u>35,484</u>	<u>108,790</u>

**6. DIRECT COSTS OF CHARITABLE ACTIVITIES**

	2020 £	2019 £
Staff costs	15,713	-
Development Expenses	6,642	640
Marketing	12,939	9,318
Miscellaneous Expense	806	49
Event Expenses	4,226	117,496
Media	13,200	16,597
Internet and Website	6,545	-
	<u>60,071</u>	<u>144,100</u>

**7. GRANTS PAYABLE**

	2020 £	2019 £
Awareness Raising	13,235	7,963
The total grants paid to institutions during the year was as follows:		
	2020 £	2019 £
ECCO	13,235	6,963
Oral Health Foundation	-	1,000
	<u>13,235</u>	<u>7,963</u>

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**8. SUPPORT COSTS**

	Finance £	Other £	Governance costs £	Totals £
Raising donations and legacies	45	5,191	779	6,015
Care and Support	28	3,776	499	4,303
Awareness Raising	92	25,423	1,623	27,138
Research for a Cure	12	3,812	219	4,043
	<u>177</u>	<u>38,202</u>	<u>3,120</u>	<u>41,499</u>

Support costs, included in the above, are as follows:

	Raising donations and legacies £	Care and Support £	Awareness Raising £
Bank charges	45	28	92
Wages	-	-	14,174
Pensions	1,212	776	2,520
Rent and Rates	2,147	1,374	4,465
Insurance	61	39	127
Fees and subscriptions	103	66	215
Telephone, printing, postage and stationery	101	65	210
Sundries	207	133	433
Travel and Meetings	-	53	53
Consultancy fees	1,360	870	2,828
Conference expenses	-	400	398
Independent Examiner's fee	660	422	1,373
Accountancy and legal fees	119	77	250
	<u>6,015</u>	<u>4,303</u>	<u>27,138</u>
		<b>2020</b>	<b>2019</b>
	Research for a Cure £	Total activities £	Total activities £
Bank charges	12	177	422
Wages	1,908	16,082	35,763
Pensions	339	4,847	4,478
Rent and Rates	601	8,587	8,192
Insurance	17	244	40
Fees and subscriptions	29	413	449
Telephone, printing, postage and stationery	28	404	870
Sundries	58	831	418
Travel and Meetings	53	159	3,512
Consultancy fees	381	5,439	4,420
	<u>3,426</u>	<u>37,183</u>	<u>58,564</u>
Carried forward			

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**8. SUPPORT COSTS - continued**

		<b>2020</b>	2019
	Research for a Cure £	Total activities £	Total activities £
Brought forward	<b>3,426</b>	<b>37,183</b>	<b>58,564</b>
Conference expenses	<b>398</b>	<b>1,196</b>	<b>193</b>
Independent Examiner's fee	<b>185</b>	<b>2,640</b>	<b>2,645</b>
Accountancy and legal fees	<b>34</b>	<b>480</b>	<b>481</b>
	<b>4,043</b>	<b>41,499</b>	<b>61,883</b>

**9. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	<b>2020</b>	2019
	£	£
Independent Examiner's fee	<b>3,000</b>	<b>2,640</b>

**10. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2020 nor for the year ended 31 December 2019.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31 December 2020 nor for the year ended 31 December 2019.

**11. STAFF COSTS**

	<b>2020</b>	2019
	£	£
Wages and salaries	<b>37,406</b>	<b>35,763</b>
Other pension costs	<b>4,847</b>	<b>4,478</b>
	<b>42,253</b>	<b>40,241</b>

The average monthly number of employees during the year was as follows:

	<b>2020</b>	2019
	1	1
Average monthly employees	<b>1</b>	<b>1</b>

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £37,406 (2019: £35,763).

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted funds £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	11,790	-	11,790
Other trading activities	428,398	-	428,398
Investment income	55	-	55
<b>Total</b>	<b>440,243</b>	<b>-</b>	<b>440,243</b>
 <b>EXPENDITURE ON</b>			
Raising funds	147,779	-	147,779
<b>Charitable activities</b>			
Care and Support	8,664	-	8,664
Awareness Raising	187,219	-	187,219
Research for a Cure	3,828	-	3,828
<b>Total</b>	<b>347,490</b>	<b>-</b>	<b>347,490</b>
 <b>NET INCOME</b>	<b>92,753</b>	<b>-</b>	<b>92,753</b>
 <b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	60,418	13,100	73,518
 <b>TOTAL FUNDS CARRIED FORWARD</b>	<b>153,171</b>	<b>13,100</b>	<b>166,271</b>

**13. TANGIBLE FIXED ASSETS**

	Plant and machinery £
<b>COST</b>	
At 1 January 2020 and 31 December 2020	<b>47,250</b>
<b>DEPRECIATION</b>	
At 1 January 2020 and 31 December 2020	<b>47,250</b>
<b>NET BOOK VALUE</b>	
At 31 December 2020	-
At 31 December 2019	-

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2020</b>	2019
	£	£
Gift aid recoverable	-	11,528
Prepayments	218	471
	<u>218</u>	<u>11,999</u>

**15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2020</b>	2019
	£	£
Social security and other taxes	5,835	4,071
Accrued expenses	3,000	2,640
	<u>8,835</u>	<u>6,711</u>

**16. LEASING AGREEMENTS**

Minimum lease payments under non-cancellable operating leases fall due as follows:

	<b>2020</b>	2019
	£	£
Within one year	-	1,925

**17. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Unrestricted funds	Restricted funds	<b>2020</b> Total funds	2019 Total funds
	£	£	£	£
Current assets	122,924	13,100	136,024	172,982
Current liabilities	(8,835)	-	(8,835)	(6,711)
	<u>114,089</u>	<u>13,100</u>	<u>127,189</u>	<u>166,271</u>

**18. MOVEMENT IN FUNDS**

	At 1.1.20	Net movement in funds	At 31.12.20
	£	£	£
<b>Unrestricted funds</b>			
General fund	153,171	(39,082)	114,089
<b>Restricted funds</b>			
Research for a Cure	13,100	-	13,100
<b>TOTAL FUNDS</b>	<u>166,271</u>	<u>(39,082)</u>	<u>127,189</u>

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

**18. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	90,186	(129,268)	(39,082)
<b>TOTAL FUNDS</b>	<u>90,186</u>	<u>(129,268)</u>	<u>(39,082)</u>

**Comparatives for movement in funds**

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
<b>Unrestricted funds</b>			
General fund	60,418	92,753	153,171
<b>Restricted funds</b>			
Research for a Cure	13,100	-	13,100
<b>TOTAL FUNDS</b>	<u>73,518</u>	<u>92,753</u>	<u>166,271</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	440,243	(347,490)	92,753
<b>TOTAL FUNDS</b>	<u>440,243</u>	<u>(347,490)</u>	<u>92,753</u>

**Capital fund**

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

**Research for a Cure Fund**

The fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2020**

---

**19. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 December 2020.

**20. GOING CONCERN**

The Trustees have considered the effect of the COVID-19 pandemic in 2020 and into 2021 on the Charity's activities. While the outbreak is likely to cause some changes to the charity's business, the Charity currently holds a comfortable level of reserves and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.



**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2020**

	2020 £	2019 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	17,061	11,790
<b>Other trading activities</b>		
Fundraising events	73,105	428,398
<b>Investment income</b>		
Deposit account interest	20	55
<b>Total incoming resources</b>	<b>90,186</b>	<b>440,243</b>
<b>EXPENDITURE</b>		
<b>Raising donations and legacies</b>		
Wages	5,611	-
Development expenses	152	638
Marketing	-	9,318
Miscellaneous expenses	-	49
Donor software subscription	1,174	1,896
Event Expenses	4,226	117,494
Media	3,300	4,149
	<b>14,463</b>	<b>133,544</b>
<b>Charitable activities</b>		
Wages	15,713	-
Development Expenses	6,642	640
Marketing	12,939	9,318
Miscellaneous Expense	806	49
Event Expenses	4,226	117,496
Media	13,200	16,597
Internet and Website	6,545	-
Grants to institutions	13,235	7,963
	<b>73,306</b>	<b>152,063</b>
<b>Support costs (Operating)</b>		
<b>Finance</b>		
Bank charges	177	422
<b>Other</b>		
Wages	16,082	35,763
Carried forward	16,082	35,763

This page does not form part of the statutory financial statements

**THE HPV AND ANAL CANCER FOUNDATION  
LIMITED**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2020**

	2020 £	2019 £
<b>Other</b>		
Brought forward	<b>16,082</b>	35,763
Pensions	<b>4,847</b>	4,478
Rent and Rates	<b>8,587</b>	8,192
Insurance	<b>244</b>	40
Fees and subscriptions	<b>413</b>	449
Telephone, printing, postage and stationery	<b>404</b>	870
Sundries	<b>831</b>	418
Travel and Meetings	<b>159</b>	3,512
Consultancy fees	<b>5,439</b>	4,420
Conference expenses	<b>1,196</b>	193
	<b>38,202</b>	58,335
<b>Governance costs</b>		
Independent Examiner's fee	<b>2,640</b>	2,645
Accountancy and legal fees	<b>480</b>	481
	<b>3,120</b>	3,126
Total resources expended	<b>129,268</b>	347,490
<b>Net (expenditure)/income</b>	<b>(39,082)</b>	92,753

This page does not form part of the statutory financial statements